In the largest study of its kind to date, a team of investigators at the Feinstein Institutes for Medical Research analyzed the electronic health records of 5,449 hospitalized COVID-19 patients between March 1, 2020, and April 5, 2020 and determined that 36.6 % (1,993 patients) developed AKI.
Among patients with AKI at the study's conclusion, 39.1 % (780 out of 1,993) were still hospitalized.
AKI is a sudden episode of kidney failure or damage, preventing waste from being filtered within the body and can often lead to death.
Most cases developed early in a patient's hospitalisation, with 37.3% either arriving with AKI or developing it within 24 hours.
The number of patients requiring dialytic support at some point during their hospitalization was 285 or 5.2% of all patients, representing 14.3% of those with AKI. The link between respiratory failure and AKI was substantial.
Among patients who required mechanical ventilation, 89.9% (1,068/1,190) developed AKI, compared to 21.7% (925/4259) in non-ventilated patients.
Among patients who required mechanical ventilation, 23.2% (276 of 1,190) developed AKI and required dialysis therapy, compared to 0.2% (9 of 4,259) in non-ventilated patients.
In comparison to data from China, respiratory disease severity appeared to be less in China, as 13.4% of the Chinese patients required mechanical ventilation compared to 21.8% of the patients in the US study.
The study also revealed risk factors for developing AKI, including age, diabetes mellitus and cardiovascular disease, hypertension, and need for ventilation and vasopressor medications. Researchers also found those of the Black race were at increased risk for developing AKI.
Future studies will look to better understand the causes of AKI and patient outcomes.
The Feinstein Institutes for Medical Research is the research arm of Northwell Health, the largest health care provider and private employer in New York State.
Home to 50 research labs, 2,500 clinical research studies and 5,000 researchers and staff, the Feinstein Institutes raises the standard of medical innovation through its five institutes of behavioral science, bioelectronic medicine, cancer, health innovations and outcomes, and molecular medicine.
Merck completes acquisition of Verona Pharma to expand cardio-pulmonary portfolio
Amgen offers Repatha through AmgenNow direct-to-patient programme
MedHub-AI's AutocathFFR receives national reimbursement approval in Japan
Early, Evidence-Led Cardiovascular Care Strengthened in High-Risk MENA Regions
Corstasis and U.S. Heart and Vascular partner to advance heart failure care with ENBUMYST
Eli Lilly and Company's orforglipron outperforms oral semaglutide in Phase 3 ACHIEVE-3 trial
Merck reports positive Phase 3 results for oral PCSK9 inhibitor enlicitide
Abbott's Navitor TAVI system granted CE Mark for expanded indication
Cereno Scientific receives FDA Fast Track designation for CS1 in pulmonary arterial hypertension
FDA lifts clinical hold on Rocket Pharmaceuticals' RP-A501 Phase 2 Danon disease trial
OptiBiotix signs distribution deal with major weight management company
Novartis to present cardiovascular abstracts portfolio data at ESC Congress in Madrid
LivaNova announces commercial launch of Essenz Perfusion System in China